Details

Autor(en) / Beteiligte

• Kelderman, Sander
• Heemskerk, Bianca
• van Tinteren, Harm
• van den Brom, Rob R. H.
• Hospers, Geke A. P.
• van den Eertwegh, Alfonsus J. M.
• Kapiteijn, Ellen W.
• de Groot, Jan Willem B.
• Soetekouw, Patricia
• Jansen, Rob L.
• Fiets, Edward
• Furness, Andrew J. S.
• Renn, Alexandra
• Krzystanek, Marcin
• Szallasi, Zoltan
• Lorigan, Paul
• Gore, Martin E.
• Schumacher, Ton N. M.
• Haanen, John B. A. G.
• Larkin, James M. G.
• Blank, Christian U.

Titel

Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma

Ist Teil von

• Cancer Immunology, Immunotherapy, 2014-05, Vol.63 (5), p.449-458

Ort / Verlag

Berlin/Heidelberg: Springer Berlin Heidelberg

Erscheinungsjahr

2014

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Introduction Ipilimumab, a cytotoxic T lymphocyte-associated antigen-4 blocking antibody, has improved overall survival (OS) in metastatic melanoma in phase III trials. However, about 80 % of patients fail to respond, and no predictive markers for benefit from therapy have been identified. We analysed a ‘real world’ population of patients treated with ipilimumab to identify markers for treatment benefit. Methods Patients with advanced cutaneous melanoma were treated in the Netherlands (NL) and the United Kingdom (UK) with ipilimumab at 3 mg/kg. Baseline characteristics and peripheral blood parameters were assessed, and patients were monitored for the occurrence of adverse events and outcomes. Results A total of 166 patients were treated in the Netherlands. Best overall response and disease control rates were 17 and 35 %, respectively. Median follow-up was 17.9 months, with a median progression-free survival of 2.9 months. Median OS was 7.5 months, and OS at 1 year was 37.8 % and at 2 years was 22.9 %. In a multivariate model, baseline serum lactate dehydrogenase (LDH) was demonstrated to be the strongest predictive factor for OS. These findings were validated in an independent cohort of 64 patients from the UK. Conclusion In both the NL and UK cohorts, long-term benefit of ipilimumab treatment was unlikely for patients with baseline serum LDH greater than twice the upper limit of normal. In the absence of prospective data, clinicians treating melanoma may wish to consider the data presented here to guide patient selection for ipilimumab therapy.